A high prevalence of TNBC (25% of cases with known receptor status) was noted, with a slightly earlier mean age at diagnosis of 55.5 ± 13.1 years compared to non-TNBC, and 72% TNBC was recorded as grade 3 carcinomas, also prevalent among HER2-enriched patients, whereas, for non-TNBC patients, only 39% of cases were grade 3 carcinomas (p < 0.0001) [17]. Here, ERBB2 is linked to carcinoma.